Centrus Energy Corp vs Viatris Inc — how do they compare? Centrus Energy Corp trades at $168.19 (market cap $3.08B), while Viatris Inc trades at $17.32 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 6.4× Centrus Energy Corp's market cap, and Viatris Inc pays a 2.83% dividend while Centrus Energy Corp pays none. Which is the better fit depends on your goals.
| LEU | VTRS | |
|---|---|---|
Market Cap | $3.08B | $19.79B |
Sector | Energy | Health |
52-Week High | $436.00 | $17.39 |
52-Week Low | $146.61 | $8.74 |
Enterprise Value | $2.39B | $32.00B |
Dividend Yield | — | 2.83% |
Signals from Pluang's Aura AI — not financial advice
Centrus Energy (LEU) trades at $156.39, showing modest daily gains amid a bearish technical outlook. The company reported mixed quarterly earnings, with a recent beat in Q1 2026 but misses in prior quarters. Positive developments include a $1 billion+ DOE contract and inclusion in the S&P SmallCap 600, highlighting its strategic role in the U.S. nuclear fuel supply chain. Valuation ratios remain elevated, with a P/E of 56.75, while profitability metrics like a 13.4% net income margin reflect solid operational performance.
The outlook for LEU is cautiously optimistic, driven by government contracts and nuclear energy tailwinds, but high valuation and recent earnings volatility pose risks. Analyst consensus is mixed with a $223.14 price target, suggesting potential upside if execution improves. Key risks include dependency on federal contracts and competitive pressures in the uranium sector.
Viatris (VTRS) trades at $17.10, down 1.1% today but maintains a bullish technical outlook with strong moving average signals. The company shows mixed fundamentals with recent earnings beats but negative profitability metrics, while analyst consensus leans toward Hold with a $20 price target. Recent positive developments include FDA acceptance of new drug applications and pipeline progress in biosimilars.
Viatris presents a value opportunity with reasonable P/S and P/B ratios, but faces challenges with negative margins and high debt. The stock's upside potential depends on successful pipeline execution and debt reduction, while risks include competitive pressures and execution missteps in a challenging pharmaceutical market.
Trailing returns across standard periods
Latest headlines on both assets
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →